The prevalence of HBsAg chronic carriers in our unit was 4.7%; it was partially related to the length of time on HD. The prevalence of previous HBV infection (40%) was not related to any of the examined factors. Recombinant hepatitis B vaccine was given to 118 chronic HD subjects with a regimen vaccination of 3-40-μg doses administered intramuscularly at 0.1 and 2 months, obtaining an immunization rate of 67% (79/118), 44/79 (56%) being high-responders. Furthermore, at month 12, 87.5% (63/72) of the responder patients maintained protective levels of anti-HBs, 48% (30/63 of them being high-responders). We found significant difference with regard to diabetes mellitus between responder and non-responder groups; serological positivity for antibodies against B core antigen facilitates the fall of anti-HBs antibodies over time.
|Translated title of the contribution||Prevention of hepatitis B infection in chronic hemodialysis (HD) patients with recombinant vaccine: A prospective study with reinforced schedule|
|Number of pages||8|
|Journal||Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia|
|Publication status||Published - 1994|
ASJC Scopus subject areas